Is NeoGenomics, Inc. (NEO) a Buy, Sell, or Hold?
NASDAQ : NEO
NeoGenomics, Inc.
$16.335 USD
-$0.2 (-1.18%)
- Volume
- 103.04K
- Average Volume
- 2.65M
- Market Capitalization
- $419.73M
- P/E Ratio
- -8.22
- Dividend Yield
- 0.00%
- Price Target
- $19.00
- Year High
- $16.92
- Year Low
- $5.94
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.60
Company Overview
NASDAQ
Anthony Zook
Medical - Diagnostics & Research
Healthcare
NEO
2500
US
USD
Liquidity Metrics
0.57
3.60
3.35
1.37
0.00
Sales & Valuation
$727.33M
0.55
0.54
-56.98
-0.28
Profitability
-$4.2
-$108.02M
-6.77%
-7.12%
-6.31%
-3.84%
P/E Metrics
-8.22
-0.15
-0.15
Analyst Price Target & Rating
$19.00
$25.00
$13.00
2/5
29 Analysts
-14.03%
Financial Health Scores
0.67
4/9
$275.6M
$1.35B
$565.65M
-$52.57M
Key Metrics (TTM)
$727.57M
0.95
56.46
3.60
-6.31%
-5.03%
-12.11%
-1.73%
22 days
Company Executives
| Name | Title |
|---|---|
| Kendra Sweeney | Vice President of Investor Relations & Communications |
| Andrew A. Lukowiak | Chief Innovation Officer |
| Anthony Zook | Chief Executive Officer & Director |
| Gary Passman | Chief People & Culture Officer |
| Warren Stone | President & Chief Operating Officer |
| Alicia Olivo | Executive Vice President of Business Development, General Counsel & Corporate Secretary |
| Clarence Cooper | Vice President of Compliance & Privacy |
| Elizabeth A. Floegel | Chief Digital & Information Officer |
| Abhishek Jain | Executive VP & CFO |
| Gregory D. Aunan | Senior Vice President & Chief Accounting Officer |
| Kareem Saad | Head of Strategy, Business Development & Transformation |
Poll Results
No votes yet today — be the first to share your view!
About NeoGenomics, Inc. (NASDAQ:NEO) Stock
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Addition ... ally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
2026-08-12 09:25:00
Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared with a 20% historical benchmark. The result was nearly 2.5 times the historical benchmark and was statistically significant at p=0.0047.
2026-08-12 08:00:00
Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days — No major toxicities reported across the cohort; adverse events predominantly low-grade — Company to host investor conference call and webcast today at 8:30 a.m. Eastern Time CALABASAS, Calif.
Neo Performance Materials Q2 Earnings Call Highlights
2026-08-11 23:05:30
Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
2026-08-10 08:30:00
NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
2026-08-04 10:15:38
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is NeoGenomics Inc (NEO) a Bargain After 3.7% Drop? GF Value Says Undervalued
2026-07-31 19:41:00
On July 31, 2026, NeoGenomics Inc (NEO) shares fell 3.7% to $15.29, reflecting a mixed price performance amid broader market movements. The stock has traded wit
NeoGenomics (NASDAQ:NEO) Reaches New 12-Month High After Earnings Beat
2026-07-30 02:01:30
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $16.10 and last traded at $15.5070, with a volume of 629708 shares changing hands. The stock had previously closed at $13.40. The medical research company reported
Frequently Asked Questions
-
What is the current NeoGenomics, Inc. (NEO) stock price?
-
NeoGenomics, Inc.(NASDAQ:NEO) stock price is $16.335 in the last trading session. During the trading session, NEO stock reached the peak price of $16.92 while $5.94 was the lowest point it dropped to. The percentage change in NEO stock occurred in the recent session was --1.18% while the dollar amount for the price change in NEO stock was -$0.2.
-
NEO's industry and sector of operation?
-
The NASDAQ listed NEO is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of NEO?
-
Kendra Sweeney | Vice President of Investor Relations & Communications
Andrew A. Lukowiak | Chief Innovation Officer
Anthony Zook | Chief Executive Officer & Director
Gary Passman | Chief People & Culture Officer
Warren Stone | President & Chief Operating Officer -
How many employees does NEO have?
-
Number of NEO employees currently stands at 2500. NEO operates from 9490 NeoGenomics Way, Fort Myers, FL 33912, US.
-
Link for NEO official website?
-
Official Website of NEO is: https://www.neogenomics.com
-
How do I contact NEO?
-
NEO could be contacted at phone #239 768 0600 and can also be accessed through its website. NEO operates from 9490 NeoGenomics Way, Fort Myers, FL 33912, US.
-
How many shares of NEO are traded daily?
-
The average number of NEO shares traded daily for last 3 months was 2.65M.
-
What is the market cap of NEO currently?
-
The market value of NEO currently stands at $419.73M with its latest stock price at $16.335